In the ongoing fight against COVID-19, the FDA has granted Emergency Use Authorization for Pemgarda, a COVID-19 infusion drug. Read on for more.
Coronavirus cell
(Adobe Stock 340164484 by phonlamaiphoto)
In a significant move to bolster protections against COVID-19, the Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Pemgarda, an infusion drug manufactured by Invivyd. This authorization is specifically for patients who are immunocompromised, offering a crucial line of defense against COVID-19 infection. The FDA emphasized in its announcement that this treatment is intended for individuals with "moderate-to-severe immune compromise due to a medical condition or due to taking immunosuppressive medications or treatments and are unlikely to mount an adequate immune response to COVID-19 vaccination."
The newly authorized drug, Pemgarda, has been approved by the FDA for use as pre-exposure prophylaxis (prevention) against COVID-19 in certain adult and adolescent populations, including individuals weighing at least 40 kilograms (approximately 88 lbs) and aged 12 and above. It is designed for those individuals with moderate-to-severe immune compromise due to medical conditions or immunosuppressive treatments, and who are unlikely to mount an adequate immune response to COVID-19 vaccination.
This authorization is a critical step in protecting vulnerable populations, including cancer patients and those patients who have undergone organ transplants, against infectious diseases during public health emergencies. By allowing the use of Pemgarda, the FDA aims to enhance the nation's public health defenses against COVID-19.
The FDA's EUA authority empowers the agency to facilitate the availability and use of medical countermeasures (MCMs) crucial for combatting various threats, including infectious diseases like COVID-19. This step is part of the FDA's ongoing efforts to respond swiftly and effectively to emerging health challenges.
Despite the imminent expiration of the COVID-19 Public Health Emergency, the FDA's authorization of treatments for emergency use is not affected. The agency affirms that existing EUAs for products will continue in effect, and new EUAs may be issued as needed based on evolving circumstances and public health needs.
This targeted authorization of Pemgarda offers a significant advancement in the arsenal of tools available to combat the ongoing COVID-19 pandemic. The FDA's authorization of Pemgarda is a pivotal step forward in protecting vulnerable populations and reducing the impact of the virus on individuals with compromised immune systems. This development underscores the agency's commitment to swift action and innovative solutions in the face of public health emergencies.
For more updates, read here about COVID-19.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
2 Commerce Drive
Cranbury, NJ 08512